177Lu-DTPA-Omburtamab for Brain Cancer

This trial explores whether 177Lu-DTPA-omburtamab, a targeted radiotherapy, is safe for children and teens with certain brain cancers that haven't responded to other treatments. Researchers will test different doses to determine the safest amount. The trial targets individuals with medulloblastoma or similar cancers that have spread to the brain or spinal cord and have not responded to standard treatments. Participants should have stable symptoms and be able to manage daily activities, even if they require some assistance, such as using a wheelchair. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the chance to be among the first to receive this new therapy.

Research shows that 177Lu-DTPA-omburtamab remains in the early stages of testing for treating brain cancer in children and teenagers. As this is an early phase trial, the primary goal is to assess the treatment's safety.

Although data is limited, similar antibody-based treatments have shown promise. For instance, earlier trials with a related drug, 131 I-omburtamab, reported side effects such as tiredness and low blood cell counts, but these were generally manageable.

Researchers are excited about 177Lu-DTPA-Omburtamab because it offers a novel approach to treating brain cancer by targeting cancer cells with precision. Unlike traditional treatments like surgery, radiation, or chemotherapy, which can affect both healthy and cancerous cells, this treatment uses a radioactive molecule, 177Lu-DTPA, that specifically binds to tumor cells. This targeted action helps to deliver radiation directly to the cancer, potentially minimizing damage to surrounding healthy brain tissue. Additionally, the treatment is being explored in multiple dose levels, ranging from 25 mCi to 100 mCi, allowing researchers to determine the most effective and safe dosage for patients.

Research has shown that 177Lu-DTPA-Omburtamab targets tumors with the B7-H3 protein. This treatment delivers radiation directly to cancer cells, potentially improving outcomes for children with brain cancer. Studies have found that similar treatments can increase survival rates by targeting specific tumor markers. Early results suggest this method might be effective for aggressive cancers like medulloblastoma, which often spread to the central nervous system (CNS). Although detailed human data on this specific treatment remains limited, the targeted approach shows promise. Participants in this trial will receive varying doses of 177Lu-DTPA-Omburtamab to evaluate its effectiveness and safety.¹²³⁵⁶